Consensus Report on "Emerging Technology for Pharmaceutical Manufacturing"

The U.S. Food and Drug Administration hereby issues a Cost Reimbursement - No Fee Contract to the National Academy of Sciences, Engineering, and Medicine for services in support of a Study and Consensus report entitled, "Identifying Innovative Technologies to Advance Pharmaceutical Manufacturing."

This Contract was awarded as a sole-source contract under the authority of FAR 6.302-5(c)(1)(iii)(B). The National Academy of Science is a sole-source provider authorized by statute, 36 U.S.C. § 150301 - 150304. Accordingly, FAR 6.302-5(c)(1)(iii)(B) applies, which states that full and open competition is not required:
"(B) To any contract requiring the National Academy of Sciences to investigate, examine, or experiment upon any subject of science or art of significance to an executive agency and to report on those matters to the Congress or any agency of the Federal Government."

This contract will result in a workshop and summary document examining the subject of scientific and regulatory topics with clear application to the FDA.

Notice of intent to sole-source this contract was posted to FBO on 5/15/2019 under the sources sought notice/solicitation# FDA-19-1214278. No capability statements were provided by interested vendors nor did any interested party contest the FDA's intent to sole-source the award.

. Awarded Vendors: National Academy of Sciences. Contract Award Dollar Amount: Not-to-Exceed $989,369.00. Contract Award Date: 2019-07-19.